ClinicalTrials.gg
CompletedNCT01338415FUTURE 3 ExtUpdated Mar 30, 2025Results posted

FUTURE 3 Study Extension

A Phase 3 interventional study of Bosentan in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed at 36 sites in 18 countries. Open to participants aged 3 Months to 12 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
58
Allocation
Non-randomized
Ages
3 Months to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing bosentan in Pulmonary Arterial Hypertension — none open to participants now, none under way, none of them phase 3. Bosentan · Pulmonary Arterial Hypertension.

Enrollment
5th of 18
58 · median 37
Started
2011
with 2 others
Phase 3
7 of 18
none open now
Registered
12th of 18
by date
Lead sponsor
10 of 18
Actelion

Among the 18 studies testing bosentan in Pulmonary Arterial Hypertension, this one is the 5th largest by enrollment, is one of 3 that started in 2011, is one of 7 in phase 3, and was the 12th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

None of the 18 studies testing bosentan in Pulmonary Arterial Hypertension is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →

About bosentan

Bosentan: first FDA approval 2001 (TRACLEER), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 3 Months to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing bosentan in Pulmonary Arterial Hypertension as a file.
02

Study summary

The objectives of the FUTURE 3 Study Extension are to evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with Pulmonary Arterial Hypertension (PAH).

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • pediatric
  • pulmonary arterial hypertension
  • bosentan
  • Tracleer
04

Who can participate

Ages eligible
3 Months to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who completed the FUTURE 3 core study (AC-052-373) or prematurely discontinued due to PAH-progression, if bosentan was not permanently discontinued
  2. Patients who tolerated bosentan pediatric formulation and for whom bosentan is considered beneficial at the end of the FUTURE 3 core study (AC-052-373)
  3. Signed by the parents or the legal representatives prior to any study-mandated procedure.

Exclusion criteria

Exclusion Criteria:

  1. Known intolerance or to bosentan or any of the of the dispersible bosentan tablet
  2. Any laboratory abnormality that precludes continuation of bosentan therapy
  3. Pregnancy
  4. and/or ALT values > 3 times the (ULN)
  5. Moderate to severe hepatic impairment, i.e., Class B or C
  6. Premature and permanent study drug discontinuation during the FUTURE 3 core study (AC-052-373)
  7. Any major violation of the FUTURE 3 core study (AC-052-373) protocol.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    bosentan 2mg/kg b.i.d.

    Patients who received 2 mg/kg bosentan twcie daily (b.i.d.) during the FUTURE 3 core study and continued with the same dose regimen during the extension study

    Drug: Bosentan

  • Experimental
    bosentan 2mg/kg t.i.d.

    Patients who received 2 mg/kg bosentan 3 times a day (t.i.d.) during the FUTURE 3 core study and continued with the same dose regimen during the extension study

    Drug: Bosentan

Interventions

  • Oral dispersible tablet administered as 2mg/kg two (b.i.d.) or three (t.i.d.) times per day

    Also known as: ACT-050088

06

What researchers measure

Primary outcomes

  1. Treatment Emergent Adverse Events (AEs) up to 7 Days After Permanent Study Drug Discontinuation

    This is the total number of subjects with at least one adverse event (serious or not serious) whether or not causally related to the study drug and presented cumulatively in the FUTURE 3 and FUTURE 3 Extension study. NOTE: FUTURE 3 extension study was exploratory and no primary efficacy and safety endpoints were defined in the protocol. So, this safety outcome measure was selected and reported as primary endpoint here.

    Time frame: Up to 62 weeks in average

Other outcomes

  1. Change From Baseline up to 12 Months of Study Treatment in the World Health Organization Functional Classification (WHO FC)

    The WHO FC indicates the severity of Pulmonary Arterial Hypertension: class I (none) to class IV (most severe). Changes from baseline to month 12 and month 18 of treatment with bosentan included: improvement (change from a higher to a lower FC), worsening (change from a lower to a higher FC) or no change/stable (same FC at baseline and at the post-baseline time point). Baseline was defined as the last valid assessment performed prior to first study drug intake in the FUTURE 3 core study.

    Time frame: At Month 12

  2. Change From Baseline up to 18 Months of Study Treatment in the World Health Organization Functional Classification (WHO FC)

    The WHO FC indicates the severity of Pulmonary Arterial Hypertension: class I (none) to class IV (most severe). Changes from baseline to month 12 and month 18 of treatment with bosentan included: improvement (change from a higher to a lower FC), worsening (change from a lower to a higher FC) or no change/stable (same FC at baseline and at the post-baseline time point). Baseline was defined as the last valid assessment performed prior to first study drug intake in the FUTURE 3 core study.

    Time frame: At Month 18

  3. Change From Baseline up to 12 Months of Study Treatment in the Global Clinical Impression Scale (GCIS)

    The GCIS is a scale used to rate the patient's current overall clinical condition ("Very Good", "Good", "Neither Good or Bad", "Bad", and "Very Bad"). Rating was performed independently by the physician and parents or legal representatives. Baseline was defined as the last valid assessment performed prior to first study drug intake in the FUTURE 3 core study.

    Time frame: At Month 12

  4. Change From Baseline up to 18 Months of Study Treatment in the Global Clinical Impression Scale (GCIS)

    The GCIS is a scale used to rate the patient's current overall clinical condition ("Very Good", "Good", "Neither Good or Bad", "Bad", and "Very Bad"). Rating was performed independently by the physician and parents or legal representatives. Baseline was defined as the last valid assessment performed prior to first study drug intake in the FUTURE 3 core study.

    Time frame: At Month 18

  5. Number of Patients With Pulmonary Arterial Hypertension (PAH) Worsening Components up to the Last Day of Treatment + 7 Days

    Number of patients with at least one PAH-worsening component (death, lung transplant, hospitalization due to PAH progression, initiation of new therapy for PAH, new/worsening right heart failure) reported cumulatively over FUTURE 3 core and extension study.

    Time frame: Up to 62 weeks in average

  6. Pulmonary Arterial Hypertension (PAH) Progression up to End of Treatment + 7 Days

    PAH progression was defined by time elapsed from the first study drug administration in the FUTURE core study to the day of the first occurrence of any of the following PAH worsening events: death, lung transplant, hospitalization due to PAH progression, initiation of new therapy for PAH or new / worsening right heart failure. Subjects without a PAH worsening event were censored at EOT + 7 days. PAH progression was estimated by Kaplan-Meier methodology and expressed by the percentage of participants free of events at different time points.

    Time frame: From baseline to Month 18

  7. Overall Survival

    Overall survival was defined as the time elapsed between the first study drug administration and death (any cause) up to end of study (Month 18 survival follow-up), regardless of whether the patient was on study treatment. Patients who died, regardless of the cause of death, were considered to have had an event. Patients last known to have been alive were censored on their date of last contact. Percentage of participants without death at different time points was estimated using Kaplan-Meier methodology.

    Time frame: From baseline to month 18

  8. Exceptional Use Treatment Period (EUTP): Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) up to 7 Days After Permanent Discontinuation of Study Drug

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset during the treatment period or that are a consequence of a pre-existing condition that has worsened since baseline.

    Time frame: Up to 7 days after discontinuation of study drug (up to 3 years and 4 months)

  9. EUTP: Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) up to 7 Days After Permanent Discontinuation of Study Drug

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAE are defined as AEs with onset during the treatment period or that are a consequence of a pre-existing condition that has worsened since baseline. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Up to 7 days after discontinuation of study drug (up to 3 years and 4 months)

  10. EUTP: Percentage of Participants With AEs Leading to Premature Discontinuation of Study Drug

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Percentage of participants with AEs leading to premature discontinuation of study drug were reported.

    Time frame: Up to 3 years and 4 months

  11. EUTP: Percentage of Participants With SAEs From 7 up to 60 Days After Permanent Discontinuation of Study Drug

    A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: From 7 up to 60 days after permanent discontinuation of study drug (up to 3 years and 4 months)

  12. EUTP: Percentage of Participants With Deaths

    Percentage of participants with deaths were reported.

    Time frame: Up to 7 days after discontinuation of study drug (up to 3 years and 4 months)

  13. EUTP: Percentage of Participants With Adverse Events of Special Interest (AESI)

    Percentage of participants with AESI including liver abnormalities and anemia were reported.

    Time frame: Up to 7 days after discontinuation of study drug (up to 3 years and 4 months)

  14. EUTP: Percentage of Participants With Treatment-emergent Marked Laboratory Abnormalities up to 7 Days After Permanent Discontinuation of Study Drug

    Percentage of participants with treatment-emergent marked laboratory abnormalities were reported.

    Time frame: Up to 7 days after discontinuation of study drug (up to 3 years and 4 months)

  15. EUTP: Percentage of Participants With Liver Function Abnormalities

    Percentage of participants with liver function abnormalities: Alanine aminotransferase (ALT) greater than (\>)3\*upper limit of normal (ULN), ALT/aspartate aminotransferase (AST) \>3\*ULN, ALT /AST \>3\*ULN and less than or equal to (\<=) 5\*ULN, ALT/AST \>5\*ULN and \<=8\*ULN, ALT/AST \>8\*ULN and ALT/AST \>3\*ULN, total bilirubin \>2\*ULN and alkaline phosphatase (ALP) \<=2\*ULN were reported.

    Time frame: Up to 7 days after discontinuation of study drug (up to 3 years and 4 months)

  16. EUTP: Percentage of Participants With Any Time Occurrence of Hemoglobin <=10 Gram Per Deciliter (g/dL) and <=8g/dL Between Baseline and up to 7 Days After End of Treatment (EOT)

    Percentage of participants with any time occurrence of hemoglobin (Hgb) less than or equal to (\<=) 10 g/dL and 8 g/dL between baseline and up to the last day of treatment + 7 days during EUTP were reported. Here "N" (number of subjects analyzed) signifies subjects who were evaluable for this outcome measure.

    Time frame: Baseline, up to 7 days after end of treatment (up to 3 years and 4 months)

07

Results

Posted Dec 11, 2017
Limitations and caveats
The study was uncontrolled and exploratory. The main purpose of exceptional use treatment period of FUTURE 3 extension was to provide participants with bosentan beyond 12-month treatment period of FUTURE 3 extension. Providing bosentan as a study treatment required monitoring safety on an individual participant-level. No formal hypothesis was formulated, therefore results were exploratory.

Participant flow

Participants in this 1-year extension study were pediatric patients who completed the 6-month randomized open-label core study AC-052-373. In addition, patients were required to have tolerated study treatment during the FUTURE 3 core study and were considered by the investigator to benefit from continued bosentan treatment.

Core + Extension
Participant flow — Core + Extension
MilestoneBosentan 2mg/kg b.i.d.Bosentan 2mg/kg t.i.d.Bosentan 2mg/kg b.i.d or t.i.d. During EUTP
Started33310
Enrolled in future 3 extension31270
Completed23220
Not completed1090
Withdrew: Adverse event860
Withdrew: Withdrawal by subject110
Withdrew: Other (pah not the main etiology of ph)020
Withdrew: Other (administrative reason)100
Exceptional Use Treatment Period
Participant flow — Exceptional Use Treatment Period
MilestoneBosentan 2mg/kg b.i.d.Bosentan 2mg/kg t.i.d.Bosentan 2mg/kg b.i.d or t.i.d. During EUTP
Started0010
Completed004
Not completed006
Withdrew: Administrative decision001
Withdrew: Ongoing at the cut-off date of 19 nov 2019003
Withdrew: Withdrawal by subject001
Withdrew: Death001

Outcome measures

PrimaryTreatment Emergent Adverse Events (AEs) up to 7 Days After Permanent Study Drug Discontinuation

This is the total number of subjects with at least one adverse event (serious or not serious) whether or not causally related to the study drug and presented cumulatively in the FUTURE 3 and FUTURE 3 Extension study. NOTE: FUTURE 3 extension study was exploratory and no primary efficacy and safety endpoints were defined in the protocol. So, this safety outcome measure was selected and reported as primary endpoint here.

Time frame:
Up to 62 weeks in average
Reported as:
Count of participants · Participants
Treatment Emergent Adverse Events (AEs) up to 7 Days After Permanent Study Drug Discontinuation
ParticipantsBosentan 2mg/kg b.i.d.Bosentan 2mg/kg t.i.d.
Treatment Emergent Adverse Events (AEs) up to 7 Days After Permanent Study Drug Discontinuation2926
Other pre-specifiedChange From Baseline up to 12 Months of Study Treatment in the World Health Organization Functional Classification (WHO FC)

The WHO FC indicates the severity of Pulmonary Arterial Hypertension: class I (none) to class IV (most severe). Changes from baseline to month 12 and month 18 of treatment with bosentan included: improvement (change from a higher to a lower FC), worsening (change from a lower to a higher FC) or no change/stable (same FC at baseline and at the post-baseline time point). Baseline was defined as the last valid assessment performed prior to first study drug intake in the FUTURE 3 core study.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Change From Baseline up to 12 Months of Study Treatment in the World Health Organization Functional Classification (WHO FC)
ParticipantsBosentan 2mg/kg b.i.d.Bosentan 2mg/kg t.i.d.
Stable WHO FC2225
Improved WHO FC73
Worsened WHO FC43
Other pre-specifiedChange From Baseline up to 18 Months of Study Treatment in the World Health Organization Functional Classification (WHO FC)

The WHO FC indicates the severity of Pulmonary Arterial Hypertension: class I (none) to class IV (most severe). Changes from baseline to month 12 and month 18 of treatment with bosentan included: improvement (change from a higher to a lower FC), worsening (change from a lower to a higher FC) or no change/stable (same FC at baseline and at the post-baseline time point). Baseline was defined as the last valid assessment performed prior to first study drug intake in the FUTURE 3 core study.

Time frame:
At Month 18
Reported as:
Count of participants · Participants
Change From Baseline up to 18 Months of Study Treatment in the World Health Organization Functional Classification (WHO FC)
ParticipantsBosentan 2mg/kg b.i.d.Bosentan 2mg/kg t.i.d.
Stable WHO FC2525
Improved WHO FC33
Worsened WHO FC53
Other pre-specifiedChange From Baseline up to 12 Months of Study Treatment in the Global Clinical Impression Scale (GCIS)

The GCIS is a scale used to rate the patient's current overall clinical condition ("Very Good", "Good", "Neither Good or Bad", "Bad", and "Very Bad"). Rating was performed independently by the physician and parents or legal representatives. Baseline was defined as the last valid assessment performed prior to first study drug intake in the FUTURE 3 core study.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Change From Baseline up to 12 Months of Study Treatment in the Global Clinical Impression Scale (GCIS)
ParticipantsBosentan 2mg/kg b.i.d.Bosentan 2mg/kg t.i.d.
Assessment by Physician — Stable1616
Assessment by Physician — Improved106
Assessment by Physician — Worsened21
Assessment by Parents/Legal representative — Stable1612
Assessment by Parents/Legal representative — Improved911
Assessment by Parents/Legal representative — Worsened30
Other pre-specifiedChange From Baseline up to 18 Months of Study Treatment in the Global Clinical Impression Scale (GCIS)

The GCIS is a scale used to rate the patient's current overall clinical condition ("Very Good", "Good", "Neither Good or Bad", "Bad", and "Very Bad"). Rating was performed independently by the physician and parents or legal representatives. Baseline was defined as the last valid assessment performed prior to first study drug intake in the FUTURE 3 core study.

Time frame:
At Month 18
Reported as:
Count of participants · Participants
Change From Baseline up to 18 Months of Study Treatment in the Global Clinical Impression Scale (GCIS)
ParticipantsBosentan 2mg/kg b.i.d.Bosentan 2mg/kg t.i.d.
Assessment by Physician — Stable912
Assessment by Physician — Improved65
Assessment by Physician — Worsened41
Assessment by Parents/Legal representative — Stable87
Assessment by Parents/Legal representative — Improved610
Assessment by Parents/Legal representative — Worsened51
Other pre-specifiedNumber of Patients With Pulmonary Arterial Hypertension (PAH) Worsening Components up to the Last Day of Treatment + 7 Days

Number of patients with at least one PAH-worsening component (death, lung transplant, hospitalization due to PAH progression, initiation of new therapy for PAH, new/worsening right heart failure) reported cumulatively over FUTURE 3 core and extension study.

Time frame:
Up to 62 weeks in average
Reported as:
Count of participants · Participants
Number of Patients With Pulmonary Arterial Hypertension (PAH) Worsening Components up to the Last Day of Treatment + 7 Days
ParticipantsBosentan 2mg/kg b.i.d.Bosentan 2mg/kg t.i.d.
At least one PAH-worsening event105
No PAH-worsening event2326
Other pre-specifiedPulmonary Arterial Hypertension (PAH) Progression up to End of Treatment + 7 Days

PAH progression was defined by time elapsed from the first study drug administration in the FUTURE core study to the day of the first occurrence of any of the following PAH worsening events: death, lung transplant, hospitalization due to PAH progression, initiation of new therapy for PAH or new / worsening right heart failure. Subjects without a PAH worsening event were censored at EOT + 7 days. PAH progression was estimated by Kaplan-Meier methodology and expressed by the percentage of participants free of events at different time points.

Time frame:
From baseline to Month 18
Reported as:
Number · Percentage of patients free of events
Pulmonary Arterial Hypertension (PAH) Progression up to End of Treatment + 7 Days
Percentage of patients free of eventsBosentan 2mg/kg b.i.d.Bosentan 2mg/kg t.i.d.
Kaplan-Meier estimate at Month 1274.9 (56.0 to 86.6)88.9 (69.4 to 96.3)
Kaplan-Meier estimate at Month 1868.2 (48.9 to 81.5)81.0 (60.1 to 91.7)
Statistical analysis
  • Bosentan 2mg/kg b.i.d. vs Bosentan 2mg/kg t.i.d. · Regression, Cox · Hazard ratio (hr): 1.438 · 95% CI 0.470 to 4.399
  • Bosentan 2mg/kg b.i.d. vs Bosentan 2mg/kg t.i.d. · Regression, Cox · p = 0.0526 (p-value \<= 10% indicates that the covariate WHO FC at baseline is related to the time to PAH worsening)
  • Bosentan 2mg/kg b.i.d. vs Bosentan 2mg/kg t.i.d. · Regression, Cox · Hazard ratio (hr): 1.169 · 95% CI 0.371 to 3.681
  • Bosentan 2mg/kg b.i.d. vs Bosentan 2mg/kg t.i.d. · log(e) likelihood ratio · p = 0.076 (p-value \<= 10% indicates an improvement in model fit)
Other pre-specifiedOverall Survival

Overall survival was defined as the time elapsed between the first study drug administration and death (any cause) up to end of study (Month 18 survival follow-up), regardless of whether the patient was on study treatment. Patients who died, regardless of the cause of death, were considered to have had an event. Patients last known to have been alive were censored on their date of last contact. Percentage of participants without death at different time points was estimated using Kaplan-Meier methodology.

Time frame:
From baseline to month 18
Reported as:
Number · Percentage of participants
Overall Survival
Percentage of participantsBosentan 2mg/kg b.i.d.Bosentan 2mg/kg t.i.d.
Kaplan-Meier estimate at Month 1281.8 (63.9 to 91.4)90.0 (72.1 to 96.7)
Kaplan-Meier estimate at Month 1875.8 (57.3 to 87.1)86.5 (68.0 to 94.7)
Statistical analysis
  • Bosentan 2mg/kg b.i.d. vs Bosentan 2mg/kg t.i.d. · Regression, Cox · Hazard ratio (hr): 1.935 · 95% CI 0.582 to 6.428
  • Bosentan 2mg/kg b.i.d. vs Bosentan 2mg/kg t.i.d. · Regression, Cox · p = 0.0085p-value \<= 10% indicates that the covariate is related to the time to the time to death up to end-of-study
  • Bosentan 2mg/kg b.i.d. vs Bosentan 2mg/kg t.i.d. · Regression, Cox · Hazard ratio (hr): 1.487 · 95% CI 0.437 to 5.052
  • Bosentan 2mg/kg b.i.d. vs Bosentan 2mg/kg t.i.d. · log(e) likelihood ratio · p = 0.014p-value \<= 10% indicates an improvement in model fit
Other pre-specifiedExceptional Use Treatment Period (EUTP): Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) up to 7 Days After Permanent Discontinuation of Study Drug

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset during the treatment period or that are a consequence of a pre-existing condition that has worsened since baseline.

Time frame:
Up to 7 days after discontinuation of study drug (up to 3 years and 4 months)
Reported as:
Number · percentage of participants
Exceptional Use Treatment Period (EUTP): Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) up to 7 Days After Permanent Discontinuation of Study Drug
percentage of participantsBosentan 2mg/kg b.i.d or t.i.d. During EUTP
Exceptional Use Treatment Period (EUTP): Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) up to 7 Days After Permanent Discontinuation of Study Drug80
Other pre-specifiedEUTP: Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) up to 7 Days After Permanent Discontinuation of Study Drug

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAE are defined as AEs with onset during the treatment period or that are a consequence of a pre-existing condition that has worsened since baseline. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Up to 7 days after discontinuation of study drug (up to 3 years and 4 months)
Reported as:
Number · percentage of participants
EUTP: Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) up to 7 Days After Permanent Discontinuation of Study Drug
percentage of participantsBosentan 2mg/kg b.i.d or t.i.d. During EUTP
EUTP: Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) up to 7 Days After Permanent Discontinuation of Study Drug40
Other pre-specifiedEUTP: Percentage of Participants With AEs Leading to Premature Discontinuation of Study Drug

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Percentage of participants with AEs leading to premature discontinuation of study drug were reported.

Time frame:
Up to 3 years and 4 months
Reported as:
Number · percentage of participants
EUTP: Percentage of Participants With AEs Leading to Premature Discontinuation of Study Drug
percentage of participantsBosentan 2mg/kg b.i.d or t.i.d. During EUTP
EUTP: Percentage of Participants With AEs Leading to Premature Discontinuation of Study Drug0
Other pre-specifiedEUTP: Percentage of Participants With SAEs From 7 up to 60 Days After Permanent Discontinuation of Study Drug

A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
From 7 up to 60 days after permanent discontinuation of study drug (up to 3 years and 4 months)
Reported as:
Number · percentage of participants
EUTP: Percentage of Participants With SAEs From 7 up to 60 Days After Permanent Discontinuation of Study Drug
percentage of participantsBosentan 2mg/kg b.i.d or t.i.d. During EUTP
EUTP: Percentage of Participants With SAEs From 7 up to 60 Days After Permanent Discontinuation of Study Drug0
Other pre-specifiedEUTP: Percentage of Participants With Deaths

Percentage of participants with deaths were reported.

Time frame:
Up to 7 days after discontinuation of study drug (up to 3 years and 4 months)
Reported as:
Number · percentage of participants
EUTP: Percentage of Participants With Deaths
percentage of participantsBosentan 2mg/kg b.i.d or t.i.d. During EUTP
EUTP: Percentage of Participants With Deaths10
Other pre-specifiedEUTP: Percentage of Participants With Adverse Events of Special Interest (AESI)

Percentage of participants with AESI including liver abnormalities and anemia were reported.

Time frame:
Up to 7 days after discontinuation of study drug (up to 3 years and 4 months)
Reported as:
Number · percentage of participants
EUTP: Percentage of Participants With Adverse Events of Special Interest (AESI)
percentage of participantsBosentan 2mg/kg b.i.d or t.i.d. During EUTP
EUTP: Percentage of Participants With Adverse Events of Special Interest (AESI)20
Other pre-specifiedEUTP: Percentage of Participants With Treatment-emergent Marked Laboratory Abnormalities up to 7 Days After Permanent Discontinuation of Study Drug

Percentage of participants with treatment-emergent marked laboratory abnormalities were reported.

Time frame:
Up to 7 days after discontinuation of study drug (up to 3 years and 4 months)
Reported as:
Number · percentage of participants
EUTP: Percentage of Participants With Treatment-emergent Marked Laboratory Abnormalities up to 7 Days After Permanent Discontinuation of Study Drug
percentage of participantsBosentan 2mg/kg b.i.d or t.i.d. During EUTP
EUTP: Percentage of Participants With Treatment-emergent Marked Laboratory Abnormalities up to 7 Days After Permanent Discontinuation of Study Drug0
Other pre-specifiedEUTP: Percentage of Participants With Liver Function Abnormalities

Percentage of participants with liver function abnormalities: Alanine aminotransferase (ALT) greater than (\>)3\*upper limit of normal (ULN), ALT/aspartate aminotransferase (AST) \>3\*ULN, ALT /AST \>3\*ULN and less than or equal to (\<=) 5\*ULN, ALT/AST \>5\*ULN and \<=8\*ULN, ALT/AST \>8\*ULN and ALT/AST \>3\*ULN, total bilirubin \>2\*ULN and alkaline phosphatase (ALP) \<=2\*ULN were reported.

Time frame:
Up to 7 days after discontinuation of study drug (up to 3 years and 4 months)
Reported as:
Number · percentage of participants
EUTP: Percentage of Participants With Liver Function Abnormalities
percentage of participantsBosentan 2mg/kg b.i.d or t.i.d. During EUTP
EUTP: Percentage of Participants With Liver Function Abnormalities0
Other pre-specifiedEUTP: Percentage of Participants With Any Time Occurrence of Hemoglobin <=10 Gram Per Deciliter (g/dL) and <=8g/dL Between Baseline and up to 7 Days After End of Treatment (EOT)

Percentage of participants with any time occurrence of hemoglobin (Hgb) less than or equal to (\<=) 10 g/dL and 8 g/dL between baseline and up to the last day of treatment + 7 days during EUTP were reported. Here "N" (number of subjects analyzed) signifies subjects who were evaluable for this outcome measure.

Time frame:
Baseline, up to 7 days after end of treatment (up to 3 years and 4 months)
Reported as:
Number · percentage of participants
EUTP: Percentage of Participants With Any Time Occurrence of Hemoglobin <=10 Gram Per Deciliter (g/dL) and <=8g/dL Between Baseline and up to 7 Days After End of Treatment (EOT)
percentage of participantsBosentan 2mg/kg b.i.d or t.i.d. During EUTP
Hgb <=10 g/dL22.2
Hgb <=8 g/dL0

Adverse events

Collected over From baseline up to end of treatment (and up to additional 60 days for serious adverse events and deaths), i.e. an average of 62 weeks and for EUTP: up to 7 days after discontinuation of study drug (approximately 3 years and 4 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bosentan 2mg/kg b.i.d.8/33 (24.2%)15/33 (45.5%)24/33 (72.7%)
Bosentan 2mg/kg t.i.d4/31 (12.9%)13/31 (41.9%)23/31 (74.2%)
Bosentan 2mg/kg b.i.d or t.i.d. During EUTP1/10 (10%)4/10 (40%)8/10 (80%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventBosentan 2mg/kg b.i.d.Bosentan 2mg/kg t.i.dBosentan 2mg/kg b.i.d or t.i.d. During EUTP
PULMONARY HYPERTENSIVE CRISISRespiratory, thoracic and mediastinal disorders0/331/312/10
PULMONARY ARTERIAL HYPERTENSIONRespiratory, thoracic and mediastinal disorders4/332/310/10
MIGRAINE WITH AURANervous system disorders1/330/311/10
PNEUMONIAInfections and infestations1/333/311/10
RESPIRATORY TRACT INFECTION VIRALInfections and infestations0/331/311/10
HaemoptysisRespiratory, thoracic and mediastinal disorders0/330/311/10
BRONCHOPNEUMONIAInfections and infestations0/332/310/10
SYNCOPENervous system disorders2/330/310/10
ATRIAL SEPTAL DEFECT REPAIRSurgical and medical procedures0/331/310/10
BODY TEMPERATURE INCREASEDInvestigations0/331/310/10
Most frequent other events
Showing 10 of 54
Most frequent other events
EventBosentan 2mg/kg b.i.d.Bosentan 2mg/kg t.i.dBosentan 2mg/kg b.i.d or t.i.d. During EUTP
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations9/3313/312/10
PYREXIAGeneral disorders5/337/313/10
VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations4/333/312/10
PNEUMONIAInfections and infestations0/330/312/10
DIARRHOEAGastrointestinal disorders2/336/310/10
VOMITINGGastrointestinal disorders4/336/310/10
NASOPHARYNGITISInfections and infestations6/335/311/10
COUGHRespiratory, thoracic and mediastinal disorders4/333/311/10
BLOOD BILIRUBIN INCREASEDInvestigations2/331/311/10
EPISTAXISRespiratory, thoracic and mediastinal disorders0/333/311/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Bosentan 2mg/kg b.i.d.Bosentan 2mg/kg t.i.d.Total
Mean4.5 ± 3.355.2 ± 3.814.8 ± 3.57
Age, Customized
Age, Customized(Participants)Bosentan 2mg/kg b.i.d.Bosentan 2mg/kg t.i.d.Total
Age Categories as per protocol — Infants and toddlers (28 days-23 months)101121
Age Categories as per protocol — Children (2-11 years)232043
Sex: Female, Male
Sex: Female, Male(Participants)Bosentan 2mg/kg b.i.d.Bosentan 2mg/kg t.i.d.Total
Female181028
Male152136
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bosentan 2mg/kg b.i.d.Bosentan 2mg/kg t.i.d.Total
Race as per protocol — Caucasian/White252348
Race as per protocol — Black123
Race as per protocol — Asian6410
Race as per protocol — Hispanic011
Race as per protocol — Other112
Pulmonary Arterial Hypertension (PAH) etiology
Pulmonary Arterial Hypertension (PAH) etiology(Participants)Bosentan 2mg/kg b.i.d.Bosentan 2mg/kg t.i.d.Total
Idiopathic141529
Heritable202
Congenital heart disease628
Associated PAH (i.e.,PAH after surgery for CHD)111324
Missing011
World Health Organization functional class (WHO FC)
World Health Organization functional class (WHO FC)(Participants)Bosentan 2mg/kg b.i.d.Bosentan 2mg/kg t.i.d.Total
FC I91019
FC II121527
FC III12618
08

Study locations

36 sites
  • The Children's Hospital - Site 9102
    Aurora, Colorado 80045, United States
  • Children's National Medical Center - Site 9104
    Washington, District of Columbia 20010, United States
  • Columbia University Medical Center Children's Hospital of New York Presbyterian - Site 9101
    New York, New York 10032, United States
  • Royal Children's Hospital Melbourne, Cardiology - Site 5001
    Parkville, 3052, Australia
  • The Republican Scientific-Practical Center "Cardiology" - Site 3001
    Minsk, 220036, Belarus
  • Cardiovascular Institute and Fuwai Hospital
    Beijing, 100037, China
  • Shanghai Children's Medical Center - Site 5102
    Shanghai, 200127, China
  • Fakultní nemocnice v Motole, dětské kardiocentrum - Site 3301
    Prague, 150 06, Czechia
  • Hopital Necker-Enfants Malades, Service de Cardiologie Pédiatrique - Site 2201
    Paris, 75743, France
  • CHU de Toulouse - Hôpital des Enfants, Service de Cardiologie Pédiatrique - Site 2202
    Toulouse, 31059, France
  • Deutsches Herzzentrum Kinderkardiologie - Site 1401
    Berlin, 13353, Germany
  • Universitätsklinikum Bonn Abteilung für Kinderkardiologie - Site 1404
    Bonn, 53113, Germany
  • Justus-Liebig-Universität Giessen, Kinderherzzentrum - Site 1403
    Giessen, 35392, Germany
  • Gottsegen György Országos Kardiológiai Intézet, Gyermekszív Központ, Gyermek Kardiológiai osztály - Site 3401
    Budapest, 1096, Hungary
  • Szegedi Tudományegyetem ÁOK Szent-Györgyi Albert Klinikai Központ, Gyermekgyógyászati Klinika és Gyermekegészségügyi Központ - Site 3402
    Szeged, 6720, Hungary
  • CARE Hospitals, Cardiology Dep. Hyderabad - Site 5302
    Hyderabad, 500001, India
  • Schneider Children's Medical Center- Institute of pediatric cardiology - Site 7101
    Petach Tikvah, 49202, Israel
  • Università Degli Studi di Padova - Dipartimento di Pediatria - Servizio di Cardiologia Pediatrica - Site 1501
    Padova, 35128, Italy
  • Ospedale Pediatrico "Bambino Gesù" - Dipartimento Medico Chirurgico di Cardiologia Pediatrica - Site 1502
    Rome, 00193, Italy
  • Instituto Nacional de Cardiologia (INC) Ignacio Chavez - Site 8401
    Mexico City, 14080, Mexico
  • Uniwersyteckie Centrum Kliniczne Klinika Kardiologii Dziecięcej i Wad Wrodzonych Serca - Site 3604
    Gdansk, 80-952, Poland
  • Wojewódzki Szpital Specjalistyczny we Wrocławiu Oddział Kardiologii Dziecięcej z pododdziałem Intensywnego Nadzoru Kardiologicznego - Site 3605
    Wroclaw, 51-124, Poland
  • RAMS Institution, Research Institute for complex issues of cardiovascular diseases, Siberian branch of the Russian Academy of Medical Sciences - Site 3805
    Kemerovo, 650002, Russian Federation
  • Scientific Center of Cardiovascular Surgery named after A.N.Bakulev of the RAMS - Site 3803
    Moscow, 121552, Russian Federation
  • Moscow Scientific Research Institute for Pediatrics and Childrens Surgery of Rosmedtechnologies - Site 3804
    Moscow, 125412, Russian Federation
  • Federal State Institution "Federal center of Heart, Blood and Endocrinology named after V.A.Almazov Rosmedtekhnologies" - Site 3802
    St. Petersberg, 197341, Russian Federation
  • State Educational Institution of Higher Professional Education "Saint Petersburg State Pediatric Medical Academy of Roszdrav" - Site 3801
    St. Petersburg, 194100, Russian Federation
  • Univerzitetska dečja klinika, Služba za kardiologiju - Site 3901
    Belgrade, 11000, Serbia
  • Institut za zdravstvenu zaštitu majke i deteta Srbije "Dr Vukan Čupić", Služba za ispitivanje i lečenje bolesti srca i krvnih sudova - Site 3902
    Belgrade, 11070, Serbia
  • Department of Paediatric Cardiology University of the Free State - Site 6001
    Bloemfontein, 9300, South Africa
  • Division of Paediatric Cardiology, Steve Biko Academic Hospital - Site 6002
    Pretoria, 0001, South Africa
  • Hospital Universitatario Vall d'Hebron, Neumologia - Site 1907
    Barcelona, 08035, Spain
  • Hospital Universitario La Paz - Paediatric Cardiology Department - Site 1906
    Madrid, 28046, Spain
  • Clinical Diagnostic Center - Pediatric Cardiovascular and ANES and Intensive Care Department - Site 4103
    Dnepropetrovsk, 49060, Ukraine
  • Gusak Ins Urgent and Recovery SUR AMS - Cardiovascular Rehabilitation Pediatric Department - Site 4101
    Donetsk, 83045, Ukraine
  • Gover INS - Scientific Practical Cardiovascular Pediatric Center - MOH Ukraine - Site 4102
    Kiev, 01135, Ukraine
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Aug 2014, 41 months.

Results were first posted in Dec 2017, 3 years 3 months after primary completion. A results delay was requested in Feb 2016.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 41 months is below that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2011
First posted
Apr 19, 2011
StartActual
Mar 8, 2011
Primary completionActual
Aug 13, 2014
CompletionActual
May 29, 2020
Results delay requested
Feb 17, 2016
Results first posted
Dec 11, 2017
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01338415
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Apr 19, 2011
Start date
Mar 8, 2011
Primary completion
Aug 13, 2014
Completion
May 29, 2020
Results posted
Dec 11, 2017
Last update
Mar 30, 2025
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bosentan

Start the discussion